Sugi Predict

Sugi Predict / Compounds / SCHEMBL260250

SCHEMBL260250

SCHEMBL260250

C[Si](C)(C)CCOCn1ccc2cccnc21

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MTNR1A P48039 1/20 0.48
▸ DGAT1 O75907 1/20 0.41
▸ DAO P14920 1/20 0.40
▸ PARP1 P09874 1/20 0.37
▸ P2RX7 Q99572 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ CDC7 O00311 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ HTR2C P28335 1/20 0.35
▸ HTR2B P41595 1/20 0.35
▸ RAPGEF4 Q8WZA2 1/20 0.34
▸ SLC22A12 Q96S37 4/20 0.34
▸ PDE10A Q9Y233 2/20 0.34
▸ CNR1 P21554 1/20 0.33
▸ CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19588441 0.82 MTNR1A (0.44) MTNR1ADAOPARP1P2RX7L3MBTL1
SCHEMBL2315637 0.79 DGAT1 (0.38) DGAT1PDE10A
SCHEMBL17675693 0.79 MTNR1A (0.46) MTNR1ADAOPARP1P2RX7L3MBTL1
SCHEMBL12009966 0.79 DGAT1 (0.43) DGAT1PDE10A
SCHEMBL29736735 0.79 DGAT1 (0.43) DGAT1PDE10A
SCHEMBL30064732 0.79 MTNR1A (0.51) MTNR1ADAOPARP1P2RX7L3MBTL1
SCHEMBL29492554 0.78 CDK4 (0.49) CYP2C19HTR2AHTR2C
SCHEMBL1258087 0.78 CDK4 (0.49) CYP2C19HTR2AHTR2C
SCHEMBL21178188 0.77 DGAT1 (0.46) MTNR1ADGAT1PDE10A
SCHEMBL20455636 0.77 DGAT1 (0.36) MTNR1ADGAT1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111048415-B Selective etching liquid composition and preparation method and application thereof 上海新阳半导体材料股份有限公司 2023-03-14 — — CN claimed
US-20260035373-A1 PYRROLOPYRIMIDINE ITK INHIBITORS ACLARIS THERAPEUTICS INC (US) 2026-02-05 — — US disclosed
US-12297203-B2 Pyrrolopyrimidine ITK inhibitors ACLARIS THERAPEUTICS, INC. (US) 2025-05-13 — — US disclosed
CN-119775261-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2025-04-08 — — CN disclosed
EP-4519265-A1 IRREVERSIBLE MUTEGFR INHIBITORS Bayer Aktiengesellschaft (DE) 2025-03-12 — — EP disclosed
CN-115427404-B Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2024-12-13 — — CN disclosed
CN-119080779-A Pyrrolopyrimidine ITK inhibitors 阿克拉瑞斯治疗股份有限公司 2024-12-06 — — CN disclosed
CN-112823005-B Pyrrolopyrimidine ITK inhibitors 阿克拉瑞斯治疗股份有限公司 2024-08-20 — — CN disclosed
CN-110891951-B Compounds of formula (I) 谢菲尔德大学 2024-08-20 — — CN disclosed
EP-3628045-B1 COMPOUNDS UNIV SHEFFIELD (GB) 2024-07-03 — — EP disclosed
US-20070265225-A1 Substituted monocyclic CGRP receptor antagonists MERCK SHARP & DOHME LLC 2007-11-15 — — US disclosed
US-20070265225-A1 Substituted monocyclic CGRP receptor antagonists MERCK SHARP & DOHME LLC 2007-11-15 — — US disclosed
US-20070265225-A1 Substituted monocyclic CGRP receptor antagonists MERCK SHARP & DOHME LLC 2007-11-15 — — US disclosed
WO-2007061677-A2 SPIROLACTAM ARYL CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-05-31 — — WO disclosed
WO-2007061692-A2 SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-05-31 — — WO disclosed
WO-2007061696-A2 SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-05-31 — — WO disclosed
WO-2007061737-A2 FUSED BICYCLIC mTOR INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2007-05-31 — — WO disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 — — US disclosed
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer OSI PHARMACEUTICALS, INC. 2007-05-17 — — US disclosed
WO-2007016087-A2 HETEROCYCLIC BENZODIAZEPINE CGRP RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2007-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035373-A1 PYRROLOPYRIMIDINE ITK INHIBITORS JAK3, JAK1, JAK2 MTNR1A 1162/4885DGAT1 4560/4885DAO 832/4885
US-12297203-B2 Pyrrolopyrimidine ITK inhibitors ITK, PDXK, DMPK MTNR1A 2433/4885DGAT1 4090/4885DAO 1744/4885
US-20070112005-A1 mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer MTOR, MAPKAP1, RPS6KA1 MTNR1A 3637/4885DGAT1 1249/4885DAO 3615/4885
US-20070265225-A1 Substituted monocyclic CGRP receptor antagonists QRFPR, CALCRL, EDNRB MTNR1A 44/4885DGAT1 4421/4885DAO 2565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.